Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Nguyen, Quan Dong
Sepah, Yasir J.
Do, Diana V.
Rahhal, Firas M.
Renfurm, Ronny W.
Funding for this research was provided by:
Astellas Pharma, Inc., Northbrook, IL
Text and Data Mining valid from 2019-08-01
1 April 2019
4 June 2019
1 August 2019